Clinical Trials Research: Offering Greater Chicago Area Patients the Latest Cancer Therapies
Staying on the leading edge of cancer care by enabling access to multiple late stage clinical trials.
A clinical trial is the process by which new therapies become standardized treatments. Not only is this process vitally important in identifying new and novel cancer-fighting treatments, it allows patients the opportunity to access care from the forefront of scientific development, including targeted and Immunotherapy(ies). If you or someone you know has a cancer that isn’t responding well to standard treatments, therapies that are currently in clinic trials may be the key to beating the disease. At Alpha Med, we work with the top pharmaceutical companies throughout the country to bring you the latest and greatest therapies.
Below you’ll find a list of the current clinical trials Alpha Med Physicians Group is participating in. We update this list whenever we start or end a trial, so we encourage you to check it regularly.
BMS CA180653-Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States.
INCB 18424-272- Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea.
CompLEEment-1-An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC).
Metastatic Colorectal Cancer
CanStem 303C (BB608-303CRC)-A Phase III Study of BBI-608 in Combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC).
Small Cell Lung Cancer
ATLANTIS (PM1183-C-003-14)-Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) who failed one prior Platinum-containing line (ATLANTIS Trial).
Non-Small Cell Lung Cancer
3000-02-001-Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer.
Metastatic Pancreatic Cancer
ARTIST 1 (AM0010-301)-A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-line Gemcitabine Containing Regimen.
Advanced Renal Cell Carcinoma
CLEAR (E7080-G000-307)-A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (The CLEAR Trial).
Strong D4191C00068-An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab +
Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG).
Module A – Post-Chemotherapy Urothelial and NonUrothelial Carcinoma of the Urinary Tract.
For more information on our current clinical trials, or to schedule an appointment, call 708-928-5040. You can also request an appointment using our easy online form on this page.